IGF-1 LR3 Research Guide: The Long-R3 Modification & IGF-1R

What Is IGF-1 LR3?

IGF-1 LR3 (Long-R3 IGF-1) is a recombinant, single-chain 83-amino-acid analog of human Insulin-like Growth Factor 1 (IGF-1). Native IGF-1 is a 70-residue protein; the "LR3" name encodes the two engineered changes that distinguish the analog. The "R3" is an arginine substituted for the native glutamic acid at position 3 of the mature IGF-1 chain, and the "Long" is a 13-residue N-terminal extension peptide added to the front of the sequence.

Those two modifications do one functionally important thing: they drastically lower the analog's affinity for the IGF-binding proteins (IGFBPs) — the carrier proteins that normally sequester and clear circulating IGF-1 — while leaving binding to the IGF-1 receptor (IGF-1R) largely intact. The result is a higher free (bioavailable) fraction and a longer functional half-life than native IGF-1, which is why IGF-1 LR3 is widely used as a defined supplement in serum-free cell culture and as a growth-factor research tool. The structural design and its rationale trace to the foundational engineering study by Francis et al. (1992, Journal of Molecular Endocrinology).

Mechanism of Action

IGF-1 LR3 acts as an agonist of the type-I IGF receptor (IGF-1R), a receptor tyrosine kinase. Ligand binding triggers IGF-1R autophosphorylation and recruitment of adaptor and substrate proteins — chiefly IRS-1 / IRS-2 and Shc — which in turn activate two principal downstream cascades:

• PI3K/Akt — associated with pro-survival, anti-apoptotic, and anabolic signaling.
• Ras/Raf/MEK/ERK (MAPK) — associated with mitogenic, proliferative signaling.

These IGF-1R-driven pathways are well documented in cell models; for example, Fu et al. (2018, International Journal of Molecular Sciences) describe IGF-1R-regulated PI3K/Akt and MAPK control of myoblast proliferation. The effects described in the literature are mitogenic and anabolic in cell and animal models; nothing here is presented beyond that scope.

What the Long-R3 Modification Actually Changes

The crucial point for research design is that the LR3 analog does not use a different receptor or a different pathway. It is the same IGF-1R agonism as native IGF-1. What the Long-R3 modifications change is upstream of the receptor: by markedly reducing sequestration by the IGF-binding proteins, they increase the bioavailable (free) fraction of the ligand and prolong its functional activity in culture and in vivo. In other words, the modification is a pharmacokinetic / availability change, not a pharmacodynamic one at the level of receptor signaling.

What the Research Literature Reports

IGF-1 LR3 has a solid primary-literature core for its identity and mechanism, and it is predominantly studied as an industrial and academic cell-culture reagent and research tool. The findings below are reported for context on what the published literature has observed; essentially all of the biological data are cell-culture and animal-model, and none of it is presented as a use indication for research-grade material.

The Foundational Engineering Study

Francis et al. (1992, Journal of Molecular Endocrinology) created the novel N-terminally extended, position-3-substituted IGF-I analogues — the Long-R3 design — specifically to dissect the relative importance of IGFBP binding versus receptor binding. The study reported that reduced IGFBP affinity yields enhanced biological potency, establishing the rationale that still defines the molecule: lower IGFBP sequestration leaves more free ligand available to the receptor.

In Vivo: Selective Organ Growth

Conlon et al. (1995, Journal of Endocrinology) reported that continuous Long-R3 IGF-I infusion in the guinea pig selectively stimulated growth of specific organs (adrenals, gut, kidneys, spleen) while reducing plasma IGF-I, IGF-II, and IGF-binding-protein concentrations. That pattern illustrates the analog's altered distribution: because it is not held in the usual IGFBP reservoir, its activity and clearance behave differently from native IGF-1.

In Vitro: Distinct Behavior From Native IGF-1

In an in vitro cell model of bovine preimplantation embryos, Prelle et al. (2001, Endocrinology) found that IGF-I and Long-R3 IGF-I produced distinct outcomes: LR3 was most efficient at stimulating early cleavage, and the two ligands regulated type-I IGF receptor and IGFBP mRNA differently. This is direct evidence that the LR3 modification changes functional behavior versus native IGF-1, even at the level of receptor and gene expression — not just availability.

Reconstitution & Handling for Research

IGF-1 LR3 is supplied as a lyophilized (freeze-dried) powder and is reconstituted into solution before laboratory use. The literature and supplier protocols describe two common diluent options:

• Bacteriostatic water (sterile water with 0.9% benzyl alcohol) — suitable for routine reconstitution and short working windows.
• Dilute acetic acid (e.g. ~0.1–1% acetic acid), or 10 mM HCl as another acidic vehicle cited by suppliers — used when better solubility or anti-aggregation behavior is needed.

The acidic-diluent rationale is grounded in peptide chemistry: mildly acidic solvents protonate basic side chains, introducing electrostatic repulsion that prevents hydrophobic self-association (aggregation) and improves dissolution of poorly-soluble peptides. Bachem's peptide-solubility technical note recommends dissolving basic peptides first in a small amount of acidic solvent (acetic or trifluoroacetic acid) before dilution, and advises test-solubilizing a small amount first.

Best-practice handling is emphasized consistently across supplier protocols:

• Add diluent slowly down the inner vial wall rather than directly onto the powder.
• Do not vortex. Swirl or gently roll the vial to avoid shear-induced aggregation and oxidation.
• Store the reconstituted solution refrigerated (2–8 °C) and protect it from repeated freeze-thaw.

Reconstitution solvent volumes and any concentration figures are operational laboratory choices, not dosing guidance — this is Research Use Only material. For more on diluents, see our peptide reconstitution guide and the comparison of bacteriostatic water vs sterile water vs acetic acid.

IGF-1 LR3 vs Native IGF-1

The central comparison is always the analog against native IGF-1. The two are closely related, but the engineered differences are exactly what make LR3 useful:

• Sequence and size — native IGF-1 is 70 amino acids (~7.6 kDa); LR3 is 83 amino acids (~9.1 kDa), adding the 13-residue N-terminal extension and the Arg-for-Glu swap at position 3.
• IGFBP affinity (the defining difference) — the LR3 modifications reduce affinity for IGF-binding proteins by roughly three orders of magnitude relative to native IGF-1 (commonly cited as ~100- to ~1000-fold lower), while IGF-1R binding is largely retained (Francis et al. 1992).
• Free fraction / functional half-life — because IGFBPs normally sequester and clear circulating IGF-1, the low-IGFBP-affinity LR3 has a larger bioavailable fraction and a longer functional half-life. Exact half-life figures vary by source and model and should be treated as approximate, not a fixed constant.
• Relative potency — Francis et al. and downstream studies report LR3 is several-fold more biologically potent than native IGF-1 in assays where IGFBPs would otherwise blunt the native ligand; in IGFBP-free systems the receptor-level potencies are more similar.
• Functional behavior — even at the receptor and gene-expression level the two are not identical. Prelle et al. (2001) showed opposite regulation of type-I IGF receptor mRNA between IGF-I and Long-R3 IGF-I.

A practical note on handling: IGF-1 LR3 is a potent IGF-1R agonist with reduced IGFBP buffering and a longer functional half-life, so it drives strong mitogenic (PI3K/Akt, MAPK) signaling. That is a research-design consideration — a reason the reagent is studied and handled carefully in proliferation and growth-factor work — not a health warning.

Evaluating Research-Grade Supply

For reproducible work with a potent growth-factor reagent, the supply chain matters as much as the molecule. When sourcing IGF-1 LR3 for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a recombinant protein of this size, the COA should report:

• HPLC purity — the analytical chromatogram and the reported purity figure for the lot.
• Mass-spec confirmation — verifying the measured mass is consistent with the expected ~9.1 kDa, which is how you confirm you actually received the 83-residue Long-R3 analog and not a truncated, native, or mislabeled sequence.
• Batch / lot number and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for the research peptides we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data.

2. Lyophilized Form and Cold-Chain Discipline

IGF-1 LR3 should arrive as a lyophilized powder. Keep it cold and sealed until reconstitution, then reconstitute with clean bacteriostatic water (or a dilute acidic diluent if better solubility is needed). Because the reconstituted protein is aggregation- and oxidation-sensitive, a vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

What is IGF-1 LR3?

It is an 83-amino-acid analog of IGF-1: native IGF-1's 70 residues plus a 13-residue N-terminal extension and an arginine substituted for glutamic acid at position 3 (Francis et al. 1992). Its approximate molecular weight is ~9.1 kDa, versus ~7.6 kDa for native IGF-1.

What does the Long-R3 modification do?

It drastically reduces the analog's affinity for the IGF-binding proteins — commonly cited as roughly 100- to 1000-fold lower than native IGF-1 — while retaining IGF-1 receptor binding. That means a larger free (bioavailable) fraction and a longer functional half-life, which is the practical reason it is favored as a defined supplement in serum-free cell culture.

How does IGF-1 LR3 work mechanistically?

It is an IGF-1R agonist that signals through the PI3K/Akt (survival/anabolic) and Ras-MAPK/ERK (mitogenic/proliferative) pathways — the same pathways as native IGF-1. The Long-R3 change is about availability (less IGFBP sequestration), not a different receptor or pathway.

How is IGF-1 LR3 different from native IGF-1 in studies?

Beyond reduced IGFBP binding, the analog can behave differently in practice: in vivo (guinea pig) LR3 infusion selectively grew certain organs while lowering plasma IGF-I/IGF-II and IGFBPs (Conlon et al. 1995), and in bovine embryos LR3 and IGF-I regulated IGF-receptor mRNA differently (Prelle et al. 2001).

What does "research-grade" mean?

It indicates the material is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (purity, mass spec, batch records). All available data on IGF-1 LR3 are preclinical; it is not pharmaceutical- or human-grade and is not approved for human or veterinary therapeutic use.